Inpatient Management of Gout: Serum Urate Testing and Allopurinol Dose Adjustment
Authors' conclusion
More than 80% of hospital admissions did not have SU measured, despite the patient receiving allopurinol. Most admissions had suboptimal management of the allopurinol dose in the context of their SU.
Study context
- Population
- Patients receiving allopurinol during admissions to Christchurch-based hospitals, March 2016 to March 2023Serum urate (SU) measured in 2950
- Participants
- 18,081 patients
- Outcome
- Rates of SU testing and allopurinol dose adjustment
- Follow-up
- During the admission
Methodological detailshospital electronic prescribing and administration (ePA) system, stratified by target SU and renal function
- Hospital ePA system
- Stratified by target SU and renal function
Main finding
As reported in the abstract
- SU measured
- 2950 (16.32%)
- Mean SU, mmol/L
- 0.37 (SD 0.12)
- SU above target (0.36 mmol/L)
- 1270 (43.05%)
- SU above target: allopurinol discontinued
- 148 (11.65%)
- SU above target: dose reduced
- 44 (3.46%)
- SU above target: dose increased
- 92 (7.24%)
- SU above target: dose unchanged
- 986 (77.63%)
Observational data: associations, not effects.
Further findings
SU above target by chronic kidney disease (CKD) stage
- CKD stage 3-5 vs CKD stage 1-2
- 78.84% vs 21.26%; P < 0.001
Stop or decrease allopurinol among those above target SU, by CKD stage
- CKD stage 3-5 vs CKD stage 1-2
- 16.4% vs 10.4%; P = 0.01
Original publication
Inpatient Management of Gout: Serum Urate Testing and Allopurinol Dose Adjustment. J Rheumatol. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →